RAB9A
MOLECULAR TARGETRAB9A, member RAS oncogene family
RAB9A (RAB9A, member RAS oncogene family) is targeted by 11 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting RAB9A
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Pueraria | 0.69 | 1 |
| 2 | Genistein | 0.69 | 1 |
| 3 | pterostilbene | 0.69 | 1 |
| 4 | amlexanox | 0.69 | 1 |
| 5 | kenpaullone | 0.69 | 1 |
| 6 | Leflunomide | 0.69 | 1 |
| 7 | Niclosamide | 0.69 | 1 |
| 8 | pd98059 | 0.69 | 1 |
| 9 | Phenelzine | 0.69 | 1 |
| 10 | Riluzole | 0.69 | 1 |
| 11 | tyrphostin ag 1295 | 0.69 | 1 |
About RAB9A as a Drug Target
RAB9A (RAB9A, member RAS oncogene family) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 11 compounds with documented RAB9A interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
RAB9A inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.